Fairchem Organics Limited (FAIRCHEMOR) Fair Value & Analysis
Basic Materials · IN · Market cap ₹8.0B
Fair value as of: Jun 29, 2026
Analysis
Fairchem Organics Limited (FAIRCHEMOR) currently trades at ₹634.40, while our model-based Fair Value estimate is ₹74.78 — implying the stock looks roughly 88.2% overvalued today. We read business quality at 97/100 (high quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Fairchem Organics Limited manufactures and sells specialty oleo chemicals and intermediate nutraceuticals. It provides nutraceuticals comprising natural and mixed tocopherol and sterol concentrates; and oleo chemicals, such as dimer, isostearic, linoleic acid, stearic, palmitic, and distilled fatty acid products, as well as monobasic acid. The company operates in India, East Asia, the Middle East, North America, South America, Europe, and Southeast Asia. It serves companies/firms that produces epoxy hardeners, paints, printing inks, natural vitamin E, pet food, soaps, pharma; makes and trades in lubricants and cosmetics; and oil drilling operations. The company was incorporated in 2019 and is based in Ahmedabad, India. Fairchem Organics Limited operates as a subsidiary of Fih Mauritius Investments Limited.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Fairchem Organics Limited (FAIRCHEMOR) undervalued?
What is the fair value of FAIRCHEMOR?
What is the quality score of FAIRCHEMOR?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.